SCHEMBL29660381

SCHEMBL29660381

CCOC(=O)C(NC(=O)c1ccc(OCC)cc1)C(=O)C(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.61
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
TAS1R3 Q7RTX0 2/20 0.57
TAS1R1 Q7RTX1 2/20 0.57
HPGD P15428 1/20 0.55
PLK1 P53350 1/20 0.54
RAB9A P51151 6/20 0.51
GAA P10253 2/20 0.51
NPC1 O15118 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.48
PKM P14618 2/20 0.48
TP53 P04637 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA4 P43681 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049530 0.87 MAPT (0.48) NPSR1MEN1KMT2ATAS1R3TAS1R1
SCHEMBL29911263 0.85 TAS1R3 (0.58) NPSR1MEN1KMT2ATAS1R3TAS1R1
SCHEMBL10294829 0.81 NPSR1 (0.72) NPSR1MEN1KMT2ATAS1R3TAS1R1
SCHEMBL5424180 0.79 TAS1R3 (0.61) NPSR1MEN1KMT2ATAS1R3TAS1R1
SCHEMBL17010274 0.76 L3MBTL1 (0.61) MEN1KMT2ARAB9AGAANPC1
SCHEMBL5782189 0.76 KMT2A (0.54) MEN1KMT2ATAS1R3TAS1R1HPGD
SCHEMBL19781301 0.76 NPSR1 (1.00) NPSR1MEN1KMT2ATAS1R3TAS1R1
SCHEMBL19781302 0.76 NPSR1 (1.00) NPSR1MEN1KMT2ATAS1R3TAS1R1
SCHEMBL17010276 0.75 ESR1 (0.56) NPSR1MEN1KMT2ATAS1R3TAS1R1
SCHEMBL20266293 0.75 TAS1R3 (0.77) NPSR1MEN1KMT2ATAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP NPSR1 4805/4885MEN1 4268/4885KMT2A 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.